These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36719527)

  • 1. β-Blockers could improve the 28-day and 3-year survival of patients with end-stage renal disease: a retrospective cohort study.
    Dong H; Zhou L; Yang L; Lu H; Cao S; Song H; Fu S
    Int Urol Nephrol; 2023 Jun; 55(6):1597-1607. PubMed ID: 36719527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.
    Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF
    BMC Cardiovasc Disord; 2016 Mar; 16():60. PubMed ID: 27012911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System.
    Modi ZJ; Lu Y; Ji N; Kapke A; Selewski DT; Dietrich X; Abbott K; Nallamothu BK; Schaubel DE; Saran R; Gipson DS
    JAMA Cardiol; 2019 Apr; 4(4):353-362. PubMed ID: 30892557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
    Zhou H; Sim JJ; Shi J; Shaw SF; Lee MS; Neyer JR; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ
    Am J Kidney Dis; 2021 May; 77(5):704-712. PubMed ID: 33010357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of β-blockers therapy on the 28-day and 3-year survival rates of end-stage renal disease patients with cardiovascular disease: a retrospective cohort study.
    Wang Y; Wu Z; Lu S; Yin L; Chen Y; Qiu C; Ng PY; Durak K; Deana C; Ding F; Zhang Z; Dai L
    Ann Transl Med; 2022 Nov; 10(22):1234. PubMed ID: 36544684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
    Berger AK; Duval S; Krumholz HM
    J Am Coll Cardiol; 2003 Jul; 42(2):201-8. PubMed ID: 12875751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of initial dialysis modality on the survival of patients with ESRD in eastern China: a propensity-matched study.
    Yao X; Lei W; Shi N; Lin W; Du X; Zhang P; Chen J
    BMC Nephrol; 2020 Jul; 21(1):310. PubMed ID: 32727426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients.
    Griffith TF; Chua BS; Allen AS; Klassen PS; Reddan DN; Szczech LA
    Am J Kidney Dis; 2003 Dec; 42(6):1260-9. PubMed ID: 14655199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
    Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.
    Ferreira JP; Couchoud C; Gregson J; Tiple A; Glowacki F; London G; Agarwal R; Rossignol P
    Nephrol Dial Transplant; 2019 Jul; 34(7):1216-1222. PubMed ID: 30590716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of dialysis modality on the survival of end-stage renal disease patients with or without cardiovascular disease.
    Wang IK; Kung PT; Kuo WY; Tsai WC; Chang YC; Liang CC; Chang CT; Yeh HC; Wang SM; Chuang FR; Wang KY; Lin CY; Huang CC
    J Nephrol; 2013; 26(2):331-41. PubMed ID: 22476965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis.
    Lin TT; Chiang JY; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Lin JL; Lin LY
    Sci Rep; 2015 Dec; 5():17731. PubMed ID: 26643783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.
    Lee HF; See LC; Chan YH; Yeh YH; Wu LS; Liu JR; Tu HT; Wang CL; Kuo CT; Chang SH
    Intern Med J; 2018 Sep; 48(9):1123-1132. PubMed ID: 29808610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycemia-Related Hospitalizations and Mortality Among Patients With Diabetes Transitioning to Dialysis.
    Rhee CM; Kovesdy CP; You AS; Sim JJ; Soohoo M; Streja E; Molnar MZ; Amin AN; Abbott K; Nguyen DV; Kalantar-Zadeh K
    Am J Kidney Dis; 2018 Nov; 72(5):701-710. PubMed ID: 30037725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease.
    Ku E; Sarnak MJ; Toto R; McCulloch CE; Lin F; Smogorzewski M; Hsu CY
    J Am Heart Assoc; 2019 Aug; 8(16):e012749. PubMed ID: 31411082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-recovery from dialysis-requiring acute kidney injury and short-term mortality and cardiovascular risk: a cohort study.
    Lee BJ; Hsu CY; Parikh RV; Leong TK; Tan TC; Walia S; Liu KD; Hsu RK; Go AS
    BMC Nephrol; 2018 Jun; 19(1):134. PubMed ID: 29890946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.
    Hruskova Z; Pippias M; Stel VS; Abad-Díez JM; Benítez Sánchez M; Caskey FJ; Collart F; De Meester J; Finne P; Heaf JG; Magaz A; Palsson R; Reisæter AV; Salama AD; Segelmark M; Traynor JP; Massy ZA; Jager KJ; Tesar V
    Am J Kidney Dis; 2019 Feb; 73(2):184-193. PubMed ID: 30122544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin Use and Increased Mortality in End-Stage Renal Disease.
    Lin MC; Streja E; Soohoo M; Hanna M; Savoj J; Kalantar-Zadeh K; Lau WL
    Am J Nephrol; 2017; 46(4):249-256. PubMed ID: 28910806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-ESRD Depression and Post-ESRD Mortality in Patients with Advanced CKD Transitioning to Dialysis.
    Molnar MZ; Streja E; Sumida K; Soohoo M; Ravel VA; Gaipov A; Potukuchi PK; Thomas F; Rhee CM; Lu JL; Kalantar-Zadeh K; Kovesdy CP
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1428-1437. PubMed ID: 28679562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Adolescent Hypertension With Future End-stage Renal Disease.
    Leiba A; Fishman B; Twig G; Gilad D; Derazne E; Shamiss A; Shohat T; Ron O; Grossman E
    JAMA Intern Med; 2019 Apr; 179(4):517-523. PubMed ID: 30801616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.